DOCSLIB.ORG

Heart Failure Guidelines Forum Better Understand the Heart Failure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Heart Failure Guidelines Forum Better Understand the Heart Failure FACULTY BIOGRAPHIES 15h & 16th October 2018 6th edition Nice France Heart Failure Guidelines Forum Better understand the Heart failure guidelinesGUIDELINES developmentGUIDELINES process FORUM by FORUM by HEART FAILURE and its implicationsHEART FAILURE GUIDELINES GUIDELINES FORUM by FORUM by PRIMARY HYPERTENSION PRIMARY HYPERTENSION GUIDELINES GUIDELINES FORUM by FORUM by COPD 1 HFGFCOPD GUIDELINES GUIDELINES CONTENTS FORUM by FORUM by LIPIDS LIPIDS Clinical practice guidelines and arise as a result of a rapidly changing associated implementation strategies clinical landscape and attempts at are essential to promote optimal, addressing unmet clinical needs. evidence-based practices in heart failure prevention and management. The Guidelines Forum on While current practice guidelines Heart Failure aims to gather a are generally in agreement, specific multidisciplinary panel of leading recommendations may differ, academic international experts and reflecting diverging interpretations industry representatives involved in of the available evidence or the basic and clinical research to discuss lack of sufficient data to make the latest evidence, ongoing research evidence-based recommendations. and controversial issues that have In addition, a number of questions implications for clinical practice. Heart Failure Guidelines Forum Chairs .........................................................................................................................3 Better understand the Heart failure Faculty Members .................................................................................................7 guidelines development process EMA representatives ......................................................................................25 and its implications 2 CONTENTS Guidelines Forum CHAIRS 3 Stefan D. Anker MD, PhD, FESC Contact: Charité Campus CVK, Division of Cardiology & Metabolism, Dept of Cardiology & BCRT, Augustenburger Platz 1, D-13353 Berlin, Germany. Stefan D. Anker is Professor of (Tissue)Homeos- Dr. Anker was Vice President of the European tasis in Cardiology & Metabolism (W3) at Cha- Society of Cardiology (ESC, 2016-18), serving rité Berlin (from June 2017). Dr. Anker studied on the ESC board 2012-2018. Dr. Anker serves medicine at Charité Berlin and completed his in the board of the Heart Failure Association clinical training in Germany and the UK. He (HFA) of the ESC since 2006; he was HFA Pre- obtained his M.D. from Charité Medical School, sident (2012-14). He is founding Editor-in-Chief Berlin, Germany (1993), and his Ph.D. (1998) at of the open access journal ESC Heart Failure. National Heart & Lung Institute of Imperial Dr. Anker worked in several ESC Guideline task College London. He was Professor of Cardiolo- forces (e.g. the ESC HF guidelines 2012 & 2016). gy & Cachexia Research (W2) at Charité (2002- Dr. Anker is the founding president of the In- 14), and Professor of Innovative Clinical Trials ternational Society on Sarcopenia, Cachexia (W3) in Göttingen (2014-17). and Wasting Disorders (SCWD – see www. cachexia.org). Dr. Anker is founding Editor- Dr. Anker has authored more than 800 origi- in-Chief of the Journal of Cachexia, Sarcopenia nal papers, reviews, and editorials that are well and Muscle (JCSM, 2016-IF: 12.51, see www. cited. For his work Dr. Anker has won several jcsm.info). Dr. Anker was and is member of >30 prizes, including the 2018 Copernicus Prize international clinical trial steering committees, of German DFG & Polish FNP. He obtained a chairing or co-chairing several currently (FAIR- number of fellowships & grants, incl. 2 from HF2, EMPEROR-HFpEF, Fair-HFpEF, EMPE- NIH (WARCEF EU), 2 EU-FP7 & 2 IMI/Ho- RIAL-HFpEF, RELIEVE-HF) as well as in the rizon2020 grants. He was co-ordinator for “SI- past (incl. FAIR-HF, TIM-HF, AUGMENT-HF, CA-HF” (EU-FP7). He received grants for three IMPULSE-HF & BACH). He served in a num- IITs that are currently running for >13 Mill EUR ber of DMC’s (chairing 4) and end-point com- (from DZHK Germany & several industries). mittees (chairing 4). 4 Gerasimos Filippatos Dean, School of Medicine University of Cyprus Professor of Cardiology, University of Cyprus & National and Kapodistrian University of Athens Gerasimos Filippatos studied Medicine at has published over 450 articles in peer-re- the University of Patras, GR, and earned viewed journals and authored more than his doctorate Cum Laude from the Univer- 30 book chapters including the “Acute sity of Athens. He subsequently completed Heart Failure” chapter in Braunwald’s and his clinical training in Chicago, USA; and Oxford Desc Reference: Cardiology. Moreo- Cambridge, UK. ver, he has (co) edited 5 books including the ESC Textbook of Acute and Intensive Prof Filippatos is past President of the Cardiac Care, Highly Commended in the Heart Failure Association (HFA) of the 2011 British Medical Association Medical European Society of Cardiology (ESC). He Book Awards; in 2014 presented the book has served as Chair of the Clinical Section Heart Failure: The Expert’s Approach and and the Committee on Acute Heart Fai- in 2016 the pocket book: Treatment Algo- lure of the HFA, and as Chair of the ESC’s rithms in Heart Failure. Working Group on Acute Cardiac Care. He was also Coordinator of the ESC Congress Prof. Filippatos is in the Thomson Reuters Programme Committee for Heart Failure list of Highly Cited Researchers. and Acute Cardiac Care, member of the ESC Practice Guidelines Committee and Honorary Member of many Cardiac Socie- American College of Cardiology/American ties: ie French Cardiac Society, Romanian Heart Association HF Guidelines Writing Cardiac Society, Hungarian Cardiac So- Committee, and International Governor of ciety. the American College of Chest Physicians. Dr. Filippatos is Associate Editor of the Euro- pean Heart Journal (impact factor>20), the International Journal of Cardiology and of the Journal of Cardiovascular Medicine. He 5 Petar M. Seferovic President, Heart failure Association of the ESC Corresponding member of Serbian Academy of Sciences and Arts Professor, University of Belgrade Faculty of Medicine and Heart Failure Center, University Medical Center, Belgrade President, Heart Failure Society of Serbia Petar Seferovic is President of the Heart His research interests mainly include heart Failure Association of the European So- failure, acute and chronic, cardiomyop ciety of Cardiology. thies, myocarditis, pericardial disease as well as cardiovascular disease and dia- He has a long standing experience in the betes. He has been involved in numerous activities of ESC, and later was involved heart failure clinical trials as a National in Heart Failure Association projects for coordinator and Principal investigator, almost a decade. member of international steering com- mittees, endpoint committees, and advi- He is a Chair of Internal medicine, Bel- sory boards. grade University School of Medicine and Professor, Heart failure Department, Prof. Seferovic has coauthored a total of University Medical Center Belgrade, 570 publications, with cumulative im- Belgrade, Serbia. After completing his pact factor of 730 (h-index 31), including training and fellowship at Belgrade multiple papers in peer-reviewed inter- University School of Medicine and Kings national journals. He has a total citation College Hospital in London, UK, he spent of 15560 (Google Scholar) / 14758 (Sco- two years as a Visiting Assistant pro- pus). He presented more than 221 lec- fessor in Methodist Hospital and Bay- tures at International conferences. lor College of Medicine, Houston, USA. Prof. Seferovic was leading the intro- He acted as a Task Force member on se- duction of several methods of interven- veral ESC guidelines, including ESC gui- tional cardiology and myocardial and delines on the diagnosis and treatment pericardial disease in Serbia, including of acute and chronic heart failure, the percutaneous transluminal angioplasty, ESC guidelines for the management of endomyocardial biopsy, percutaneous pericardial disease, and the guidelines pericardioscopy and pericardial biopsy. on cardiovascular diseases in diabetes. In Starting mid-90’s, he dedicated his clini- addition, Petar Seferovic serves as a re- cal and research activity to chronic and viewer for several journals. acute heart failure. He is Corresponding member of Serbian Academy of Scien- cies and Arts and President, Heart Fai- lure Society of Serbia 6 Guidelines Forum FACULTY 7 William T. Abraham M.D., F.A.C.P., F.A.C.C., F.A.H.A., F.E.S.C., F.R.C.P. Professor of Internal Medicine, Physiology and Cell Biology Chair of Excellence in Cardiovascular Medicine Associate Dean for Clinical Research Chief, Division of Cardiovascular Medicine Medical Director, Clinical Trials Management Office Deputy Director, Dorothy M. Davis Heart and Lung Research Institute The Ohio State University, Columbus, Ohio Dr. Abraham earned his medical degree from Harvard and vasopressin receptor antagonists; and acute Medical School in Boston, Massachusetts, following heart failure and renal dysfunction complicating which he completed his residency in Internal heart failure. His work has contributed to the approval Medicine and fellowships in Cardiovascular Disease and adoption of several therapies for heart failure, and Advanced Heart Failure/Transplant Cardiology at including beta-blockers, natriuretic peptides, cardiac the University of Colorado Health Sciences Center. He resynchronization therapy, ultrafiltration devices, previously held leadership positions at the University
Load more

Recommended publications
  • Heartbeat Heart: First Published As 10.1136/Heartjnl-2020-318759 on 22 December 2020
    Heartbeat Heart: first published as 10.1136/heartjnl-2020-318759 on 22 December 2020. Downloaded from Heartbeat: an increase in preventable cardiovascular deaths during the COVID-19 pandemic due to avoidance of medical care doi:10.1136/heartjnl-2020-318759 Catherine M Otto Patients with cardiovascular disease (CVD) have an increased mortality risk with COVID-19 infection yet several studies have shown fewer hospital- based CVD diagnoses and procedures during the COVID-19 pandemic. In this issue of Heart, Wu and colleagues1 show that despite a decrease in the number of patients presenting with an acute CVD event there was an 8% excess of CVD deaths in England between March and June 2020 (during the COVID-19 pandemic), compared with the previous 6 years (figure 1). About ½ of these deaths occurred outside the hospital with the most frequent causes of CVD death being stroke (35.6%), acute coronary syndrome (24.5%), heart failure (23.4%) pulmonary embolism (9.3%) and cardiac arrest (4.6%). Most of these deaths were not related to a known COVID-19 infec- tion, suggesting they were most likely due to delays in seeking medical care or Figure 1 Time series of acute cardiovascular (CV) deaths, by place of death. The number of daily undiagnosed COVID-19 infection. CV deaths is presented using a 7-day simple moving average (indicating the mean number of As Singh and Newby2 emphasise in daily CV deaths for that day and the preceding 6 days) from 1 February 2020 up to and including 30 June 2020, adjusted for seasonality. The number of non- COVID-19 excess CV deaths each day an editorial: ‘the evidence presented by http://heart.bmj.com/ Wu and colleagues1 provides us with an from 1 February 2020 were subtracted from the expected daily death estimated using Farrington important message to our patients and surveillance algorithm in the same time period.
    [Show full text]
  • Web of Science and Scopus Are Not Global Databases of Knowledge
    Tennant JP. Web of Science and Scopus are not global databases of knowledge. European Science Editing 2020;46. DOI: 10.3897/ ese.2020.e51987 VIEWPOINT Web of Science and Scopus are not global databases of knowledge Jonathan P Tennant† Institute for Globally Distributed Open Research and Education (IGDORE), UK; ORCID 0000-0001-7794-0218 DOI: 10.3897/ese.2020.e51987 Abstract Both Web of Science and Scopus are critical components of the current research ecosystem, providing the basis for university and global rankings as well as for bibliometric research. However, both platforms are structurally biased against research produced in non-Western countries, non-English language research, and research from the arts, humanities, and social sciences. This viewpoint emphasizes the damage that these systematic inequities inflict upon global knowledge production systems and the need for research funders to unite to form a more globally representative, non-profit, community-controlled infrastructure for the global pool of research knowledge. There has never been a more pressing need for science to be example, features prominently in the UK Research Excellence working to address the major challenges that we face as a global Framework 2021 and in international league tables, and society, as envisaged by the UN Sustainable Development bibliographic data from Scopus represent more than 36% of Goals.1 The earth’s climate is changing catastrophically and assessment criteria in the popular Times Higher Education irreversibly; we are in the midst of yet another global pandemic world university rankings. 2; and we are facing resource distribution inequities like never Cameron Neylon and others criticize these rankings, before in the face of a booming global population.
    [Show full text]
  • Valvular Heart Disease CLASS (STRENGTH) of RECOMMENDATION LEVEL (QUALITY) of EVIDENCE‡ CLASS 1 (STRONG) Benefit >>> Risk LEVEL A
    Clinical Update ADAPTED FROM: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease CLASS (STRENGTH) OF RECOMMENDATION LEVEL (QUALITY) OF EVIDENCE‡ CLASS 1 (STRONG) Benefit >>> Risk LEVEL A Suggested phrases for writing recommendations: • High-quality evidence‡ from more than 1 RCT • Is recommended • Meta-analyses of high-quality RCTs • Is indicated/useful/effective/beneficial • One or more RCTs corroborated by high-quality registry studies • Should be performed/administered/other Table 1. • Comparative-Effectiveness Phrases†: LEVEL B-R (Randomized) − Treatment/strategy A is recommended/indicated in preference to • Moderate-quality evidence‡ from 1 or more RCTs treatment B ACC/AHA • Meta-analyses of moderate-quality RCTs − Treatment A should be chosen over treatment B LEVEL B-NR (Nonrandomized) Applying Class of CLASS 2a (MODERATE) Benefit >> Risk • Moderate-quality evidence‡ from 1 or more well-designed, well- Suggested phrases for writing recommendations: executed nonrandomized studies, observational studies, or registry Recommendation Is reasonable • studies • Can be useful/effective/beneficial • Meta-analyses of such studies and Level of • Comparative-Effectiveness Phrases†: − Treatment/strategy A is probably recommended/indicated in preference to LEVEL C-LD (Limited Data) treatment B Evidence to − It is reasonable to choose treatment A over treatment B • Randomized or nonrandomized observational or registry studies with limitations of design or execution Clinical Strategies, CLASS 2b (Weak) Benefit ≥ Risk • Meta-analyses of such studies • Physiological or mechanistic studies in human subjects Suggested phrases for writing recommendations: Interventions, • May/might be reasonable LEVEL C-EO (Expert Opinion) • May/might be considered Treatments, or • Usefulness/effectiveness is unknown/unclear/uncertain or not well-established • Consensus of expert opinion based on clinical experience.
    [Show full text]
  • Clinical Science Meet the Editor-In-Chief: Rhian M. Touyz
    News Portland Press News IMPACT FACTOR: 4.859* AT THE INTERFACE OF CLINICAL RESEARCH & DISCOVERY SCIENCE Clinical Science Meet the Editor-in-Chief: Rhian M. Touyz Downloaded from http://portlandpress.com/biochemist/article-pdf/36/1/73/6273/bio036010073.pdf by guest on 30 September 2021 Professor Rhian Touyz is the Editor- I have to acknowledge and thank in-Chief of Clinical Science. She is the the past Editor-in-Chief, Professor British Heart Foundation (BHF) Chair Clinton Webb, and his editorial team, in Cardiovascular Medicine, focusing who laid the path for the growth in the on research related to molecular, cellular Impact Factor. Not only is the Journal and vascular mechanisms of experimental receiving more submissions, but the and clinical hypertension. She is the quality of papers submitted continues Director of the Institute of Cardiovascular to increase. The Journal provides an and Medical Sciences, BHF Glasgow ideal medium in which to publish Cardiovascular Research Centre, translational research, a field that is University of Glasgow, Glasgow, UK. becoming increasingly more popular. Rhian received her BSc (Hons) Clinical Science attracts papers from (1980), MBBCh (1984), MSc (1986) and PhD (1992) many disciplines, since it covers a broad spectrum of from the University of the Witwatersrand, Johannesburg, biomedical specialities, including the cardiovascular South Africa. She completed a post-doctoral fellowship system, cerebrovascular system, gastrointestinal tract (1992–1996) at the Clinical Research Institute of and liver, genetics and functional genomics, infection Montreal, Montreal, Quebec, Canada. and immunity, inflammation and oncology, metabolism, Rhian co-chaired the Recommendations Task Force endocrinology and nutrition, nephrology and of the Canadian Hypertension Education Program circulation, respiratory system and vascular biology.
    [Show full text]
  • The Risk for Chronic Kidney Disease in Patients with Heart Diseases
    Liu et al. BMC Nephrology 2012, 13:77 http://www.biomedcentral.com/1471-2369/13/77 RESEARCH ARTICLE Open Access The risk for chronic kidney disease in patients with heart diseases: a 7-year follow-up in a cohort study in Taiwan Jiung-Hsiun Liu1,2,3, Shih-Yi Lin1,3, Chung-Yi Hsu4, Hsin-Hung Lin1,3, Chih-Chia Liang1, Fung-Chang Sung2,4* and Chiu-Ching Huang1,3* Abstract Background: The worldwide increasing trend of chronic kidney disease (CKD) is of great concern and the role of heart disease deserves longitudinal studies. This study investigated the risk of developing CKD among patients with heart diseases. Methods: From universal insurance claims data in Taiwan, we retrospectively identified a cohort of 26005 patients with newly diagnosed heart diseases and 52010 people without such disease from the 2000–2001 claims. We observed prospectively both cohorts until the end of 2007 to measure CKD incidence rates in both cohorts and hazard ratios (HR) of CKD. Results: The incidence of CKD in the cohort with heart disease was 4.1 times greater than that in the comparison cohort (39.5 vs. 9.65 per 10,000 person-years). However, the HR changed into 2.37 (95% confidence interval (CI) = 2.05 – 2.74) in the multivariate Cox proportional hazard model after controlling for sociodemographic characteristics and comorbidity. Compared with individuals aged < 40 years, the HRs for CKD ranged from 2.70 to 4.99 in older age groups. Significant estimated relative risks of CKD observed in our patients were also independently associated with hypertension (HR = 2.26, 95% CI = 1.94 - 2.63) and diabetes mellitus (HR = 2.44, 95% CI = 2.13 - 2.80), but not with hyperlipidemia (HR =1.13, 95% CI = 0.99-1.30).
    [Show full text]
  • An Overview of Cardiovascular Disease and Research
    WORKING P A P E R An overview of cardiovascular disease and research EDWARD NASON WR-467-RS January 2007 Prepared for Project Retrosight This product is part of the RAND Europe working paper series. RAND working papers are intended to share researchers’ latest findings and to solicit additional peer review. This paper has been peer reviewed but not edited. Unless otherwise indicated, working papers can be quoted and cited without permission of the author, provided the source is clearly referred to as a working paper. RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors. is a registered trademark. RAND Europe Cardiovascular research overview Preface This working paper has been prepared for the International consortium of cardiovascular disease (CVD) research funders involve in Project Retrosight. Project Retrosight is investigating the payback on CVD research in four countries (Australia, Britain, Canada and New Zealand). The main objective of this suite of documents is to provide an overview of the CVD situation, CVD research and the funding systems in place for CVD research. This background information will be useful in providing context to the case studies of specific CVD research projects that form the majority of Project Retrosight. Each country involved in the project will produce 4-16 case studies of research conducted around the early 1990s, following the outputs and outcomes from that research. The case studies will use the Payback framework used by the UK study team in previous health research studies.1 This document provides an overview of the key background issues involved in this study of research into CVD.
    [Show full text]
  • Instructions for Authors Netherlands Heart Journal
    Instructions for authors Netherlands Heart Journal Aims and scope The scope of the Netherlands Heart Journal (NHJ) is to contribute to the national and international literature by publishing scientific papers in the field of cardiovascular medicine. The journal aims to publish high-quality papers on a wide spectrum of cardiovascular medicine, with a focus on both clinical and experimental observations. It also provides a platform for Continuing Medical Education for cardiologists and those in training for the specialty of cardiology in the Netherlands. NHJ is made available to cardiologists, cardiologists in training, cardiopulmonary surgeons, cardiopulmonary surgeons in training, internists and paediatric cardiologists. The journal is the official journal of the Netherlands Society of Cardiology. There are no author publication charges to submit or publish an article in the journal and the full-text of all articles is freely available immediately upon publication. Articles are published with a Creative Commons attribution license (CC BY) and the author(s) retain the copyright of their article. NHJ is an English language, a single-blind peer-reviewed journal and is published 11 times a year. Open access NHJ is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access. All articles are free to access and download from: http://link.springer.com/journal/12471.
    [Show full text]
  • Top 100 Cited Articles in Cardiovascular Magnetic Resonance: a Bibliometric Analysis Muhammad Shahzeb Khan1, Waqas Ullah2, Irbaz Bin Riaz3, Nizar Bhulani4, Warren J
    Khan et al. Journal of Cardiovascular Magnetic Resonance (2016) 18:87 DOI 10.1186/s12968-016-0303-9 REVIEW Open Access Top 100 cited articles in cardiovascular magnetic resonance: a bibliometric analysis Muhammad Shahzeb Khan1, Waqas Ullah2, Irbaz Bin Riaz3, Nizar Bhulani4, Warren J. Manning5*, Srini Tridandapani6 and Faisal Khosa7 Abstract Background: With limited health care resources, bibliometric studies can help guide researchers and research funding agencies towards areas where reallocation or increase in research activity is warranted. Bibliometric analyses have been published in many specialties and sub-specialties but our literature search did not reveal a bibliometric analysis on Cardiovascular Magnetic Resonance (CMR). The main objective of the study was to identify the trends of the top 100 cited articles on CMR research. Methods: Web of Science (WOS) search was used to create a database of all English language scientific journals. This search was then cross-referenced with a similar search term query of Scopus® to identify articles that may have been missed on the initial search. Articles were ranked by citation count and screened by two independent reviewers. Results: Citations for the top 100 articles ranged from 178 to 1925 with a median of 319.5. Only 17 articles were cited more than 500 times, and the vast majority (n=72) were cited between 200–499 times. More than half of the articles (n=52) were from the United States of America, and more than one quarter (n=21) from the United Kingdom. More than four fifth (n=86) of the articles were published between the time period 2000–2014 with only 1 article published before 1990.
    [Show full text]
  • Contents Heartbeat Editorials Review Aortic and Vascular Disease Arrhythmias and Sudden Death Coronary Artery Disease Healthcar
    01 June 2021 Volume 107 Issue 11 107 Impact 11 Factor 5.213 Volume 107 Issue 11 Pages 855–93 Contents Volume 107 Issue 11 | HEART 01 June 2021 heart 6 Editor’s choice Sexism experienced by consultant cardiologists in the United Kingdom Heart failure and cardiomyopathies HEART Improving the diagnosis of heart failure in Heartbeat Healthcare delivery, economics and patients with atrial fibrillation Aortic and vascular disease Safety, efficacy and impact on frailty of mini- invasive radial balloon aortic valvuloplasty Education in Heart 855 Heartbeat: time to address sexism and sexual Antithrombotic therapy for patients with chronic coronary syndromes global health harassment in cardiology 895 Sexism experienced by consultant cardiologists C M Otto in the United Kingdom 01 June 2021 heart.bmj.com S K Jaijee, C Kamau-Mitchell, G W Mikhail, C Hendry Heart: first published as on 1 June 2021. Downloaded from Journal of the British Cardiovascular Society Editorials 858 Does radial balloon aortic valvuloplasty have a place in the TAVI era? Guidelines for Authors and Heart failure and cardiomyopathies D Bongiovanni, P Presbitero Reviewers 902 Improving the diagnosis of heart failure in Full instructions are available online at patients with atrial fibrillation http://heart.bmj.com/pages/authors. 860 Women in cardiology: no progress in the pace K V Bunting, S K Gill, A Sitch, S Mehta, Articles must be submitted electronically of change K O’Connor, G YH Lip, P Kirchhof, V Y Strauss, https://mc.manuscriptcentral.com/heart. S V Babu-Narayan, S Ray K Rahimi, A J Camm, M Stanbury, M Griffith, Authors retain copyright but are required J N Townend, G V Gkoutos, A Karwath, R P Steeds, to grant Heart an exclusive licence 862 Consecutive, index and representative beats: D Kotecha, on behalf of the RAte control Therapy to publish (http://authors.bmj.com/ Evaluation in permanent Atrial Fibrillation (RATE-AF) submitting-your-paper/copyright-and- obtaining reliable information despite an trial group authors-rights/).
    [Show full text]
  • Pali Momi Heart Center – MEET OUR HEART CARE TEAM
    PALI MOMI HEART CENTER – MEET OUR HEART CARE TEAM Michael W. Chan, M.D., Jeffrey H. Chung, M.D. Muhammad Ghumman, FACC Cardiology, M.D., FACC Cardiovascular Disease, Electrophysiology Cardiology, Interventional Nuclear Cardiology Phone: (808) 485-4553 Cardiology Phone: (808) 486-6200 Phone: (808) 485-4553 MEDICAL SCHOOL: University of California, MEDICAL SCHOOL: Harvard Medical School MEDICAL SCHOOL: New York University Irvine RESIDENCY: Massachusetts General Hospital RESIDENCY: New York University Langone RESIDENCY: Baylor Affiliated Hospitals, TX Medical Center FELLOWSHIP: New York Presbyterian Hospital FELLOWSHIP: University of Chicago, IL, Weill Cornell, Electrophysiology FELLOWSHIP: New York University Cardiology Langone Medical Center Dr. Chung joined Pali Momi Medical Center Dr. Chan began his practice at Pali in 2011. He is board certified in cardio- Dr. Ghumman joined Pali Momi in 2014. Momi in 1994. He specializes in inter- vascular disease, clinical electrophysiology He is Board Certified in echocardiography, ventional and clinical cardiology and is and internal medicine. His special interests internal medicine and cardiovascular board certified in cardiovascular disease include management and treatment of disease. His hobbies include outdoor and nuclear cardiology. He currently abnormal heart rhythms, such as atrial activities and sports, Dr. Ghumman was an serves as the Chair of our Cardiology fibrillation and ventricular tachycardias. accomplished high school athlete and has and Critical Care committee here at Pali Dr. Chung was born and raised in Hawai‘i, competed as a semi-pro basketball player Momi Medical Center. and is a graduate of Punahou School. in New York. Brandon K. Itagaki, M.D. John A. Kao, M.D., FACC Abhijeet Koli, M.D.
    [Show full text]
  • Table of Contents (PDF)
    Contents Volume 94 Number 9 |HEARTSeptember 2008 Featured editorial Coronary artery disease 1105 What explains declining coronary mortality? 1154 Combining dual-source computed tomography Lessons and warnings coronary angiography and calcium scoring: added value for the assessment of coronary artery S Capewell, M O’Flaherty disease Heart: first published as on 1 September 2008. Downloaded from Editorials S Leschka, H Scheffel, L Desbiolles, A Plass, 1109 Stroke risk in the elderly: it’s not all about O Gaemperli, P Stolzmann, M Genoni, T Luescher, visible clot B Marincek, P Kaufmann, H Alkadhi Journal of the British Cardiovascular Society P Kanagaratnam Interventional cardiology 1111 Low-density lipoprotein and aortic stenosis 1162 The impact of lesion length and vessel size on outcomes after sirolimus-eluting stent Guidelines for Authors and N M Rajamannan Reviewers implantation for in-stent restenosis Full instructions are available online 1113 Alternatives to warfarin in atrial fibrillation: S Habara, K Mitsudo, T Goto, K Kadota, S Fujii, at http://heart.bmj.com/ifora. Articles drugs and devices H Yamamoto, H Kato, S Takenaka, Y Fuku, must be submitted electronically http:// Y L Bayard, S H Ostermayer, H Sievert S Hosogi, A Hirono, K Yamamoto, H Tanaka, submit-heart.bmj.com. Authors retain 1117 Myocardial oedema: a forgotten entity D Hasegawa, Y Nakamura, H Tasaka, S Otsuru, copyright but are required to grant Heart YOkamoto,CYamada,MMiyamoto,KInoue an exclusive licence to publish http:// essential to the understanding of regional
    [Show full text]
  • Heart, Lung and Circulation
    HEART, LUNG AND CIRCULATION AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Impact Factor p.1 • Editorial Board p.1 • Guide for Authors p.4 ISSN: 1443-9506 DESCRIPTION . Heart, Lung and Circulation publishes articles integrating clinical and research activities in the fields of basic cardiovascular science, clinical cardiology and cardiac surgery, with a focus on emerging issues in cardiovascular disease. The journal promotes multidisciplinary dialogue between cardiologists, cardiothoracic surgeons, cardio-pulmonary physicians and cardiovascular scientists. The journal accepts original articles, current reviews, brief communications, and letters to the Editor, concerned with clinical practice and research in all fields of cardiovascular disease. The journal particularly invites submissions concerned with the issues of cardiovascular ageing, indigenous cardiovascular health, devices, tissue repair and replacement. To purchase books on Cardiology or to browse our comprehensive range of Medical titles, please visit us at shop.elsevier.com.au. http://www.elsevierhealth.com.au/medicine-surgery/cardiology IMPACT FACTOR . 2020: 2.975 © Clarivate Analytics Journal Citation Reports 2021 EDITORIAL BOARD . Editor-in-Chief A. Robert Denniss, Westmead Hospital, Sydney, NSW, Australia Commissioning Editor Ann Gregory, Cardiac Society of Australia and New Zealand, Sydney, 2000, NSW, Australia Editorial Manager Deborah Edward, Cardiac Society of Australia and New Zealand, Sydney, 2000, Australia Founding Editor Franklin Rosenfeldt, Swinburne University of Technology Centre for Human Psychopharmacology, Melbourne, Vic, Australia Heart Rhythm Editors Kim Hoe Chan, Royal Prince Alfred Hospital, Sydney, NSW, Australia AUTHOR INFORMATION PACK 2 Oct 2021 www.elsevier.com/locate/hlc 1 Haris M. Haqqani, University of Queensland, Brisbane, Qld, Australia Saurabh Kumar, Westmead Hospital, New South Wales, Australia Dennis H.
    [Show full text]